Business Wire

60 Million Drivers Now Insured Through Telematics, PTOLEMUS Finds - UBI Market Set to Reach €200 Billion by 2035

Share

The Usage-Based Insurance (UBI) market has now reached over 60 million customers across 450 active programmes – a sixfold increase in just ten years. PTOLEMUS Consulting Group, which predicted the “uberisation” of insurance in 2015, highlights this transformation in its new report.

UBI is now a truly global phenomenon that reaches 59 countries and generates more than €50 billion in premiums, finds the consulting firm in its new report.

This growth reflects the growing smartphonisation of the business. Insurers increasingly embed UBI into their corporate apps, making it a central part of the customer experience.

At the same time, UBI has evolved beyond simple Pay-As-You-Drive (PAYD) or Pay-How-You-Drive (PHYD) models. It is now a proven tool for reducing the frequency and severity of claims, delivering measurable savings to both insurers and policyholders.

Frederic Bruneteau, Managing Director, said: “Whenever insurers propose attractive UBI programmes, customers prefer these to traditional flat-rate, proxy-based offers. As the cost of telematics has become negligible and the benefits more tangible, we expect more and more insurers to make it the central part of their digitalisation strategy.”

PTOLEMUS predicts that by 2035, 180 million vehicles globally will be insured with telematics policies, generating more than €200 billion in premiums for insurers.

Leveraging 65 interviews and the experience from 100 consulting projects, the 1,350-page report includes an analysis of 41 UBI implementation successes and the evaluation of 32 suppliers. Finally the study analyses the progress of telematics in 59 countries from Argentina to the USA and forecasts the market development until 2035.

The free abstract, featuring interviews with 5 leading industry figures, can be found on www.ptolemus.com.

About PTOLEMUS Consulting Group

PTOLEMUS is the first strategy consulting firm entirely focused on connected mobility. It assists leading insurers, OEMs, service providers in defining and executing their strategies and the end-to-end development of their telematics programmes.

For more information about the study, please contact us at contact@ptolemus.com Tel: +32 487 96 19 02.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909180488/en/

Contacts

contact@ptolemus.com
Tel: +32 487 96 19 02.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quectel Expands LTE Portfolio with Direct-to-Cell (D2C) Capabilities Enabling 100 Percent Global Reach for IoT Developers11.9.2025 14:00:00 EEST | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced that several of its LTE modules are now available with Direct-to-Cell (D2C) functionality, enabling devices to seamlessly connect to satellite networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911087809/en/ Quectel expands LTE portfolio with Direct-to-Cell (D2C) capabilities enabling 100 percent global reach for IoT developers By integrating D2C technology at the module level, Quectel enables devices to extend beyond the limits of ground-based cellular networks by seamlessly leveraging satellite networks. This ensures customers can stay connected virtually anywhere in the world, eliminating the connectivity gaps often encountered in rural or remote areas. Ultimately, this will help to simplify IoT deployments, reducing time-to-market and lowering costs by eliminating the need for specialized satellite hardware. Device manufactur

G Squared and ROYC Announce Strategic Technology Partnership11.9.2025 11:00:00 EEST | Press release

ROYC, the leading global Platform-as-a-Service provider for alternative investments, and G Squared, a U.S.-based venture capital firm investing in category-defining technology companies, are pleased to announce a strategic partnership where ROYC will act as G Squared’s technology and infrastructure partner in Europe. This partnership underscores both firms’ commitment to using best-in-class technology to improve the investor experience. ROYC’s platform will provide G Squared with a fully digital, modular solution for onboarding, execution, and portfolio management tailored to the regulatory and operational landscape in Europe. “We are excited to partner with G Squared — a firm that shares our conviction that technology is the foundation for delivering a great investor experience and G Squared’s innovation-driven DNA and long-term view make them an ideal partner, and we are proud to provide the infrastructure that will support their continued European growth”, said Octavian Popescu, CEO

Telekom Srbija Expands and Extends Partnership with SES11.9.2025 10:52:00 EEST | Press release

SES announced today the expansion of its partnership with Telekom Srbija, adding two additional transponders and extending its capacity agreements through 2032. Telekom Srbija will use the added capacity to consolidate its m:Sat TV platform at the 23.5 degrees East orbital position to grow its direct-to-home (DTH) television base across Serbia, Bosnia and Herzegovina, Montenegro and North Macedonia. The two companies first joined forces in 2011, with expanded renewals in 2020 and 2024. Under the new agreement, SES will continue to provide capacity on multiple transponders to support a broad lineup of SD and HD channels throughout the region, alongside uplink and backup services and redundant fiber connectivity for the platform. Satellite remains the infrastructure of choice of when it comes to high-quality content broadcasting in the region, underscoring its key value proposition as a reliable and cost-effective video delivery to large audiences. “The continued expansion of our partner

Quectel Introduces Four New GNSS Antennas, Backed With Advanced GNSS Modules and Worldwide RTK Support, to Maximize Developer Choice11.9.2025 10:00:00 EEST | Press release

Quectel Wireless Solutions, a global IoT solutions provider, has introduced four new additions to its comprehensive range of global navigation satellite system (GNSS) antennas. The new antennas include the YFGD000AA high precision, low profile antenna which covers all GNSS bands, the YFGD000BA, optimized for triple-band solutions in GNSS L1, L2 and L5 bands, the YFGN000H1AC high precision, lightweight antenna that again covers all GNSS bands, and the YEGT010W1AM, designed for general-purpose reception in non-precision applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911732128/en/ Quectel introduces four new GNSS antennas, backed with advanced GNSS modules and worldwide RTK support, to maximize developer choice Quectel’s triple-band and all-band antennas are purpose-built to maximize performance with the latest generation of RTK GNSS modules. These include the LC29H dual-band module, designed for cost-sensitive

ENHERTU ® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors11.9.2025 09:30:00 EEST | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with HER2 positive (immunohistochemistry [IHC] 3+) unresectable or metastatic solid tumors who have received prior treatment and have no satisfactory alternative treatment options. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from three phase 2 trials including DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 where ENHERTU demonstrated clinically meaningful responses across a broad range of tumors. “ENHERTU has shown a clinically

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye